SON-3015 / Sonnet BioTherap - LARVOL DELTA

Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update (Issuer Direct) - "'We are starting our combination study using SON-1010 with atezolizumab in Australia and are working to enroll several cohorts by the end of this year'....The DSMB overseeing the study is expected to meet during the third calendar quarter of 2023. Following the completion of the DSMB review, we anticipate announcing initial safety data from the CIPN study and will consider initiating a Phase 2 study in DPN....Research and development expenses were $2.4 million for the three months ended June 30, 2023, compared to $5.6 million for the three months ended June 30, 2022. The decrease of $3.2 million was primarily due to the establishment of cost savings by transitioning product development activities to cost advantaged locations such as India and Australia and by reducing expenditures on tertiary programs such as SON-3015, which has been placed on a development hold, as well as a decrease in share-based compensation expense."

Commercial • New trial • P2 data • Diabetic Neuropathy • Oncology

Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update (BioSpace) - "Sonnet provided the following corporate updates for the 2022 calendar year: Generating additional clinical product stability data for SON-1010 for the FDA in 1Q22; SON-1010 is on track for clinical study initiation in 2Q22...Completed R&D manufacturing for SON-1210 with initiation of a non-GLP pre-clinical toxicity study in non-human primateson track for 1H22. Completed sequence confirmation for SON-3015 and preparing for initial in vivo mice studies in 2H22. Lead optimization is underway to initiate CMC with cell line development for SON-1410 in 2Q22."

New molecule • New trial • Preclinical • Oncology

Sonnet BioTherapeutics Provides 2021 Business Update (BioSpace) - “SON-1210 (IL12-FHAB-IL15)…expects completion of NHP studies in the second half of this year with an IND submission during the first half of 2022; SON-3015 (Anti-IL6-FHAB-Anti-TGFβ): Sonnet is in the discovery phase of SON-3015 development and is currently panning the candidate for binding and stability, after which the preclinical bispecific product will be evaluated in a mice model, expected during the second half of 2021. Sonnet is planning to initiate commercial cell line development in the first quarter of 2022.”

IND • Preclinical • Oncology